Evidence reviewed: 8 November 2026. Prostate cancer is a cancer that develops in the prostate gland, commonly involving its glandular cells. Most early prostate cancers cause no symptoms, and urinary difficulty is not proof of malignancy. As cancer advances it may cause urinary symptoms, blood in urine or semen, or persistent pain if it spreads to bones. Recognizing concerning changes and obtaining appropriate tests matters, but prostate-specific antigen (PSA), a rectal examination or an MRI cannot by themselves establish the diagnosis in most patients. Specialist evaluation and usually a biopsy are needed [1–3].
Why prostate cancer often has no early symptoms
The prostate lies beneath the bladder and surrounds part of the urethra. Many cancers begin in the gland’s peripheral region, where small tumors may grow without blocking urine flow. Therefore, a person can have localized prostate cancer while urinating normally. The CDC and 2026 EAU guideline emphasize that most early cancers are asymptomatic; waiting for symptoms is not a reliable early-detection approach [1,2].
Men without symptoms should discuss the potential benefits and harms of risk-adapted PSA screening according to age, family history and other risk factors. For detailed age-related recommendations, see our 2026 prostate cancer screening, PSA and MRI guide.
Possible signs and symptoms
- Difficulty starting urination or a weak, interrupted urinary stream.
- Increased urinary frequency, particularly at night, or an urgent need to urinate.
- Difficulty emptying the bladder or a sensation of incomplete emptying.
- Blood in urine (hematuria) or blood in semen (hematospermia).
- Painful urination or ejaculation, although infections and other causes are often responsible.
- New erectile difficulties, which have many common non-cancer causes.
- Persistent back, hip or pelvic pain, especially if cancer has spread to bone.
- Unexplained weight loss, fatigue or reduced mobility in some advanced cases.
These symptoms are not specific to prostate cancer. Benign prostatic hyperplasia (BPH), urinary tract infection, prostatitis, urethral narrowing and other conditions can produce similar changes. Many people with prostate cancer have no urinary symptoms; conversely, most older men with nocturia or a weak stream do not have a cancer diagnosis [1–3].
When is urgent care needed?
Seek prompt clinical evaluation for new blood in urine, repeated urinary changes, persistent bone pain, unexplained weight loss or worsening symptoms. Urinary retention—inability to pass urine with significant discomfort—needs urgent attention.
Emergency warning signs: severe new back pain with leg weakness, numbness, difficulty walking, or changes in bladder or bowel control may indicate metastatic spinal cord compression, a time-critical emergency that requires immediate hospital evaluation. Do not wait for a scheduled clinic visit. Severe bleeding, inability to urinate, or systemic illness with fever and confusion are also reasons for urgent care.
Who has an increased risk?
Risk rises with older age. It is also higher in some individuals with Black ancestry, African descent, a strong family history or inherited mutations such as BRCA2. Other genetic variants may contribute, especially when multiple relatives on one side of a family have prostate, breast, ovarian or related cancers. These factors inform screening and, in selected families, genetic counseling [2,4].
Risk does not mean inevitability. A person with no family history can still develop prostate cancer; and a person with elevated risk may never develop it. Because some tumors are slow-growing, identifying cancer does not automatically mean immediate surgery or radiation is necessary.
How is suspected prostate cancer investigated?
A clinician begins with symptoms, examination, medication history, family history and previous PSA results. Common steps include:
- PSA blood test: a screening or diagnostic risk marker. Elevation is possible with cancer, BPH, inflammation or other causes.
- Digital rectal examination (DRE): assessment for suspicious firmness or nodularity, but not a definitive diagnostic test.
- Repeat PSA and individual risk estimation: particularly when an initial elevation may be temporary or does not fit the overall picture.
- Prostate MRI: selected patients undergo multiparametric MRI to identify suspicious regions and plan biopsy.
- Prostate biopsy: microscopic examination of tissue, usually necessary to confirm the diagnosis and characterize tumor grade.
- Staging tests: specialized imaging may be considered based on pathology, PSA, clinical features and suspected spread [2,4].
The 2026 AUA/SUO amendment updated aspects of PSA screening, MRI and biopsy selection. A negative MRI does not rule out all clinically significant cancer, and an elevated PSA does not mean that every patient needs an immediate biopsy [4].
What does a PSA number mean?
PSA is a protein produced by prostate tissue. A result is interpreted alongside age, prostate size, symptoms, family history, prior values and medicines. Finasteride and dutasteride can reduce PSA and change its interpretation. Infection, inflammation or recent procedures can also influence results. No one PSA threshold proves cancer or guarantees that cancer is absent.
PSA velocity and PSA density may contribute context, but no single mathematical rate of increase should be used independently as a biopsy decision. Updated guidance supports integrated risk assessment, sometimes with repeat PSA and MRI [2,4].
How does a biopsy result describe the cancer?
Pathologists examine biopsy samples for cancer and report features including Gleason score and ISUP Grade Group. The Grade Group system runs from 1 to 5; broadly, higher groups indicate more aggressive microscopic patterns. Grade is different from stage: grade describes how cancer cells look, whereas stage summarizes how far disease extends [2].
| Finding | Why it matters |
|---|---|
| Gleason score / ISUP Grade Group | Helps characterize tumor aggressiveness and recurrence risk. |
| Number and extent of positive biopsy cores | Provides context for disease burden and risk stratification. |
| PSA | Supports baseline risk assessment and later monitoring. |
| Clinical T stage | Describes extent within or beyond the prostate. |
| Nodal or distant spread | Helps distinguish localized, regional and metastatic disease. |
Do not infer stage from symptoms alone or from PSA without other clinical information. A patient with localized cancer may have a high PSA; another with metastatic cancer may have relatively modest urinary symptoms.
What tests determine stage?
Staging depends on biopsy pathology, clinical findings and risk. Prostate MRI may evaluate local tumor extension, while PSMA PET imaging is increasingly used for selected higher-risk staging situations or suspected recurrence, subject to access and guidelines. Bone imaging or CT may be used in other settings [2,5].
Routine whole-body imaging is not needed for every low-risk cancer. Decisions should reflect whether imaging is likely to change treatment and whether the test is appropriate for the tumor’s characteristics.
Treatment: not all prostate cancers need immediate intervention
Treatment depends on stage, Grade Group, PSA, age, overall health, life expectancy, comorbidities and preferences. The 2026 AUA/ASTRO localized prostate cancer amendment and NCI treatment guidance emphasize shared decision-making and risk-adapted choices [5,6].
| Situation | Common management options |
|---|---|
| Low-risk localized cancer | Active surveillance for many eligible patients, with treatment if risk changes. |
| Intermediate-risk localized cancer | Selected surveillance or radical prostatectomy, radiation therapy or other risk-specific approaches. |
| High-risk localized or locally advanced cancer | Multimodal care such as surgery with selected additional treatment or radiotherapy plus androgen deprivation therapy (ADT), depending on features. |
| Metastatic disease | Systemic hormonal therapies and other selected agents, potentially including chemotherapy, targeted treatment and supportive care. |
These are broad approaches, not a treatment algorithm for a particular person. Focal therapies and newer treatment modalities have variable evidence and eligibility and should not be presented as routine replacements for established options.
Active surveillance versus watchful waiting
Active surveillance is a structured plan for selected cancers judged unlikely to cause near-term harm. It typically includes repeat PSA, clinical assessments, prostate MRI when indicated, and repeat biopsies at appropriate intervals. The objective is to avoid unnecessary immediate treatment while keeping the option of curative therapy if signs of progression appear [6].
Watchful waiting is different: it is generally less intensive monitoring with the aim of relieving symptoms if they arise, often used when life expectancy or other illnesses make curative treatment less beneficial. Neither approach means the doctor has “missed” a diagnosis or that all cancers can safely be ignored.
Surgery: radical prostatectomy
Radical prostatectomy removes the prostate and surrounding structures as indicated. It can be performed using open, laparoscopic or robotic-assisted approaches in appropriate patients. Important potential adverse effects include urinary incontinence, erectile dysfunction, bleeding, infection and changes to ejaculation or fertility. Results depend on cancer extent, baseline function, nerve preservation where feasible and surgical expertise [6].
Robotic surgery is not a guarantee of better cancer survival or absence of complications. An individualized discussion should include the surgeon’s experience and the patient’s priorities.
Radiation therapy
External-beam radiation therapy and, in certain circumstances, brachytherapy are established options for localized prostate cancer. Radiation planning aims to treat cancer while reducing injury to nearby urinary, bowel and sexual structures. Some risk categories benefit from combining radiation with androgen deprivation therapy for an appropriate duration [6].
Possible adverse effects include urinary urgency, bowel irritation and erectile difficulties, some of which can develop or persist after treatment. The best option is not based solely on whether treatment requires an operation.
Androgen deprivation and modern advanced-disease therapy
Prostate cancer cells often rely on androgen receptor signaling. Androgen deprivation therapy (ADT) lowers testosterone production or blocks androgen effects. Common drug approaches include GnRH agonists or antagonists and selected androgen receptor pathway inhibitors such as abiraterone, enzalutamide, apalutamide or darolutamide according to disease state and licensing. Chemotherapy such as docetaxel, selected PARP inhibitors, radiopharmaceuticals or other targeted options may be appropriate in specific advanced cases [6].
ADT is not testosterone replacement. It can cause hot flashes, sexual dysfunction, loss of muscle or bone mass, fatigue and metabolic changes; monitoring and supportive care are important. It is not suitable to recommend one advanced cancer drug based on symptoms without staging and tumor characteristics.
What does prostate cancer have to do with back pain?
Advanced disease may spread to bone, often involving the spine, pelvis or hips. Persistent or progressive bone pain in someone with known prostate cancer should prompt assessment. However, most ordinary lower-back pain is not prostate cancer. Severe spinal pain with weakness, sensory loss or bladder/bowel changes is an emergency because metastatic spinal cord compression can damage nerves quickly.
What happens after treatment?
Follow-up generally includes serial PSA testing, monitoring of urinary and sexual function, assessment of treatment adverse effects and appropriate imaging if recurrence is suspected. PSA patterns differ after prostatectomy versus radiotherapy; clinicians interpret results using the relevant treatment-specific definitions. Long-term supportive care may include pelvic-floor rehabilitation, erectile function management, bone health, exercise, nutrition and psychological support.
Frequently asked questions
Does prostate cancer always cause a weak urinary stream?
No. Most early cancers are asymptomatic, and BPH often causes similar urinary symptoms [1,2].
Does blood in the urine mean cancer?
Not necessarily. It has several possible causes, but visible blood in urine needs medical evaluation.
Can MRI confirm prostate cancer by itself?
Usually not. MRI helps identify suspicious regions; tissue biopsy generally confirms and grades cancer [2,4].
Do all prostate cancers require immediate surgery?
No. Many eligible low-risk localized cancers are managed with active surveillance [6].
Can prostate cancer cause leg weakness?
Advanced cancer may sometimes compress the spinal cord. New weakness with severe back pain or bladder/bowel changes is an emergency.
Is PSA screening recommended for everyone?
No. Screening is a separate risk-based discussion involving benefits, harms, age and overall health. See our companion screening guide [4].
Key takeaways
Early prostate cancer is commonly silent. Urinary symptoms are nonspecific, but unexplained blood in urine, persistent bone pain or progressive symptoms warrant assessment. PSA and MRI inform risk; biopsy usually establishes the diagnosis. Treatment ranges from active surveillance to surgery, radiation or systemic therapy based on tumor risk and personal priorities.
References
- Centers for Disease Control and Prevention. Symptoms of prostate cancer. Reviewed 2026; accessed 8 Nov 2026.
- European Association of Urology. 2026 EAU prostate cancer guideline: diagnostic evaluation. Accessed 8 Nov 2026.
- National Health Service. Symptoms of prostate cancer. Accessed 8 Nov 2026.
- Lin DW, Carlsson S, Filson CP, et al. Updates to early detection of prostate cancer: AUA/SUO guideline. J Urol. 2026;215:491–501. doi:10.1097/JU.0000000000004995.
- Eastham JA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline amendment. J Urol. 2026. doi:10.1097/JU.0000000000005060.
- National Cancer Institute. Prostate cancer treatment (PDQ): patient version. Accessed 8 Nov 2026.
Medical disclaimer: Educational information only. Prostate cancer evaluation, grading and treatment require qualified clinicians. New severe back pain with weakness or bladder/bowel dysfunction, or inability to urinate, may be an emergency and warrants immediate medical care.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.